Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Clasificación en acciones #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Precio por acción
$8.74
Última sincronización: 2026-08-28
Capitalización bursátil
$699.74M
Cambio (1 día)
-4.85%
Cambio (1 año)
-2.29%
País
US
Comercio BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoría

Historial del precio de la acción de BridgeBio Oncology Therapeutics Inc. (BBOT)
Precio más alto de cierre: $9.16 el 2026-08-01

Precio más bajo de cierre: $10.40 el 2024-02-01
Historial del precio de la acción de BridgeBio Oncology Therapeutics Inc. desde 2024 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -16.90%
2025 15.50%
2024 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH